Scorpius Holdings Inc. · OTC:SCPX
Scorpius — Heat Biologics — Investor Presentation (September 2015)
13 slides from Scorpius's investor presentation, Sep 1, 2015
Slide 1: Combining HS-110 and anti-PD-1 in NSCLC
Combining HS-110 and anti-PD-1 in NSCLC September 1, 2015
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expec
Slide 3: Checkpoint Combination Rationale
Checkpoint Combination Rationale Preclinical Synergy withanti-PD-1 Bladder trial informing ImPACT responsive population Immune Response from Phase 2 NSCLC trial Changing landscape in NSCLC Checkpoint Combination Strategy for HS-110 *
Slide 4: * Copyright Heat Biologics 2015
* 1 2 3 4 Copyright Heat Biologics 2015
Slide 5: Scientific Support for HS-110 & Nivolumab Combination
Scientific Support for HS-110 & Nivolumab Combination * Pre-clinical studies demonstrate synergy between ImPACT vaccines and anti-PD-1Phase 2 clinical data demonstrate that HS-110 treated patients upregulate PD-1 on CD8+ T cellsPhase 2 tumor biopsies show strong PD-L1 staining Cohen, R.B. et al, ASC
Slide 6: Bladder Cancer Patient Histology Data
Bladder Cancer Patient Histology Data * Responder/non-responder phenotype emerging:Responder: TIL-/PD-L1-Non-responder: TIL+/PD-L1+
Slide 7: Design Intended to Broaden Responses to Nivolumab
* Design Intended to Broaden Responses to Nivolumab
Slide 8: Design Intended to Broaden Responses to Nivolumab
Design Intended to Broaden Responses to Nivolumab * Estimated 45% NSCLC patients being underserved by single-agent anti-PD-(L)1 and may benefit from vaccine combination Teng et al., 2015 Can ResGettinger et al., 2015 JCO Approx. 50% PD-1 ORR Approx. 10% PD-1 ORR
Slide 9: Checkpoint Combination Rationale
Checkpoint Combination Rationale Preclinical Synergy withanti-PD-1 Bladder trial informing ImPACT responsive population Immune Response from Phase 2 NSCLC trial Changing landscape in NSCLC Checkpoint Combination Strategy for HS-110 *
Slide 10: Response to Checkpoint Inhibitors by PD-L1 Status
Response to Checkpoint Inhibitors by PD-L1 Status * Population HS-110 combination intends to address Source: Velcheti et al. Lab Inv 2014; Gettinger et al., 2015 JCO
Slide 11: DURGA Multi-arm Combination Trial
DURGA Multi-arm Combination Trial * Provides operational platform to:React quickly to changing landscapeLeverage potential synergy with PD-1 mAbEvaluate TILs as a potential biomarker to improve response rate (Yale Cancer Center’s Translational Immuno-Oncology Laboratory collaboration) Expand cohorts
Slide 12: Clinical Development Milestones
Clinical Development Milestones Milestone Target Date First dose combination with nivo in NSCLC (Durga) 31-Aug-2015 Durga 18 pts enrolled Q2 2016 Durga immune response Q2 2016 Durga top-line readout for nivo (18 pts) Q4 2016 Ph 2 combo with cyclophosphamide readout (~65 pts) Q4 2016 Registration-dir
Slide 13: Summary
Summary * First combination vaccine + nivolumab in NSCLCStrong preclinical/clinical rationale for combinationTargeting patients unresponsive to checkpoints Data for nivo combo expected by end 2016 Registration-directed trial initiation remains on schedule (end 2016/early 2017)Bladder program on trac
Heat Biologics — Investor Presentation (September 2015) on 6ix